| Nucala |
761122 |
002 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
761122 |
003 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Emgality |
761063 |
003 |
351(a) |
galcanezumab-gnlm |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2019/06/04
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Zolgensma |
125694 |
001 |
351(a) |
onasemnogene abeparvovec-xioi |
Injection |
Intravenous |
2x10^13VG/ML |
Single-Dose Vial |
2019/05/24
|
Novartis Gene Therapies, Inc. |
Rx |
Licensed |
|
N/A |
| Herzuma |
761091 |
002 |
351(k) Biosimilar |
trastuzumab-pkrb |
For injection |
Intravenous |
150MG |
Single-Dose Vial |
2019/05/16
|
CELLTRION, Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Dengvaxia |
125682 |
001 |
351(a) |
Dengue Tetravalent Vaccine, Live |
For Injection |
Subcutaneous |
4.5-6.0 LOG10 CCID50 CCID50: CELL CULTURE INFECTIOUS DOSE 50 |
Single-Dose Vial |
2019/05/01
|
Sanofi Pasteur Inc. |
Rx |
Licensed |
|
N/A |
| Eticovo |
761066 |
001 |
351(k) Interchangeable |
etanercept-ykro |
Injection |
Subcutaneous |
50MG/ML |
Pre-Filled Syringe |
2019/04/25
|
Samsung Bioepis Co., Ltd. |
Disc |
Licensed |
etanercept |
Enbrel |
| Eticovo |
761066 |
002 |
351(k) Interchangeable |
etanercept-ykro |
Injection |
Subcutaneous |
25MG/0.5ML |
Pre-Filled Syringe |
2019/04/25
|
Samsung Bioepis Co., Ltd. |
Disc |
Licensed |
etanercept |
Enbrel |
| Skyrizi |
761105 |
001 |
351(a) |
risankizumab-rzaa |
Injection |
Subcutaneous |
75MG/0.83ML |
Pre-Filled Syringe |
2019/04/23
|
AbbVie Inc. |
Disc |
Licensed |
N/A |
N/A |
| Ogivri |
761074 |
002 |
351(k) Biosimilar |
trastuzumab-dkst |
For Injection |
Intravenous |
150MG |
Single-Dose Vial |
2019/04/17
|
Biocon Biologics Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Zemaira |
125078 |
002 |
351(a) |
Alpha-1-Proteinase Inhibitor (Human) |
For Injection |
Intravenous |
4000MG |
Single-Dose Vial |
2019/04/16
|
CSL Behring LLC |
Rx |
Licensed |
|
N/A |
| Zemaira |
125078 |
003 |
351(a) |
Alpha-1-Proteinase Inhibitor (Human) |
For Injection |
Intravenous |
5000MG |
Single-Dose Vial |
2019/04/16
|
CSL Behring LLC |
Rx |
Licensed |
|
N/A |
| Evenity |
761062 |
001 |
351(a) |
romosozumab-aqqg |
Injection |
Subcutaneous |
105MG/1.17ML |
Pre-Filled Syringe |
2019/04/09
|
Amgen Inc. |
Rx |
Licensed |
N/A |
N/A |
| Asceniv |
125590 |
001 |
351(a) |
Immune Globulin Intravenous, Human-slra |
Injection |
Intravenous |
5G/50ML |
Single-Dose Vial |
2019/04/01
|
ADMA Biologics, Inc. |
Rx |
Licensed |
|
N/A |
| Cimzia |
125160 |
002 |
351(a) |
certolizumab pegol |
Injection |
Subcutaneous |
200MG/ML |
Pre-Filled Syringe |
2019/03/28
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Aimovig |
761077 |
003 |
351(a) |
erenumab-aooe |
Injection |
Subcutaneous |
140MG/ML |
Autoinjector |
2019/03/11
|
Amgen Inc. |
Rx |
Licensed |
N/A |
N/A |
| Aimovig |
761077 |
004 |
351(a) |
erenumab-aooe |
Injection |
Subcutaneous |
140MG/ML |
Pre-Filled Syringe |
2019/03/11
|
Amgen Inc. |
Disc |
Licensed |
N/A |
N/A |
| Trazimera |
761081 |
001 |
351(k) Biosimilar |
trastuzumab-qyyp |
For Injection |
Intravenous |
420MG |
Multi-Dose Vial |
2019/03/11
|
Pfizer Ireland Pharmaceuticals |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Tecentriq |
761034 |
002 |
351(a) |
atezolizumab |
Injection |
Intravenous |
840MG/14ML (60MG/ML) |
Single-Dose Vial |
2019/03/08
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Herceptin Hylecta |
761106 |
001 |
351(a) |
trastuzumab and hyaluronidase-oysk |
Injection |
Subcutaneous |
600MG/5ML;10,000 UNITS/5ML (120MG/2,000UNITS/ML) |
Single-Dose Vial |
2019/02/28
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |